Another trial of idebenone shows that, although safe and well tolerated, the substance doesn't lead to significant improvement in Friedreich's ataxia
posted on May 28, 2010 - 12:09pm
Idebenone, a substance believed to act as an antioxidant and to aid in energy production in cellular structures called mitochondria, has failed to benefit people with Friedreich's ataxia (FA) in a phase 3 trial conducted at several European centers. The drug is similar to coenzyme Q10, a naturally occurring molecule.
Idebenone, an antioxidant and possible cellular energy booster, will be tested in some 240 boys with DMD
posted on October 8, 2009 - 10:27am
This story was updated 11/9/10 with contact information for this trial and information about clinical trials in general.
Pediatric Neurologist Richard Finkel, co-director of the MDA neuromuscular disease clinic at Children's Hospital of Philadelphia, will be the lead investigator for the North American arm of a large international trial with idebenone in Duchenne muscular dystrophy (DMD).